PW Medtech Sets Arm’s-Length Framework for Intra-Group Medical Components Sales

The latest update is out from PW Medtech Group Ltd. ( (HK:1358) ).

PW Medtech Group’s subsidiary Beijing Fert has signed a sale of medical components framework agreement with Sichuan Ruijian Medical, covering blood purification consumables and related components for internal group transactions. The framework, effective from March 27 to December 31, 2026 with possible renewals, allows group members to enter individual sales contracts specifying product types, pricing methods, delivery, and payment terms while standardizing intra-group supply.

Pricing for the components will be set with reference to market rates obtained from comparable transactions in the medical components industry and must be no less favorable than terms offered to independent third parties. Beijing Fert will periodically collect quotations from at least two independent purchasers to benchmark prices, a process designed to ensure arm’s-length dealings, compliance with Hong Kong listing rules on continuing connected transactions, and fair treatment of minority shareholders.

The most recent analyst rating on (HK:1358) stock is a Buy with a HK$1.50 price target. To see the full list of analyst forecasts on PW Medtech Group Ltd. stock, see the HK:1358 Stock Forecast page.

More about PW Medtech Group Ltd.

PW Medtech Group Limited is a Cayman Islands–incorporated medical technology company focused on manufacturing and supplying medical components and consumables. Through subsidiaries including Beijing Fert, the group serves the blood purification and wider medical devices market, supplying components such as blood purification consumables to healthcare-related counterparties in mainland China.

Average Trading Volume: 713,658

Technical Sentiment Signal: Hold

Current Market Cap: HK$1.49B

For an in-depth examination of 1358 stock, go to TipRanks’ Overview page.